[HTML][HTML] Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7 …
DJ Isaacman, ED McIntosh, RR Reinert - International Journal of Infectious …, 2010 - Elsevier
OBJECTIVES: The overall reported burden of invasive pneumococcal disease (IPD) varies
among countries in Europe. This review describes the epidemiology and serotype …
among countries in Europe. This review describes the epidemiology and serotype …
Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010–2012
WHB Demczuk, I Martin, A Griffith… - Canadian journal of …, 2013 - cdnsciencepub.com
The introduction of the 7-valent pneumococcal vaccine (PCV7) in Canada was very effective
in reducing invasive pneumococcal disease (IPD) in children; however, increases of non …
in reducing invasive pneumococcal disease (IPD) in children; however, increases of non …
Declining serotype coverage of new pneumococcal conjugate vaccines relating to the carriage of Streptococcus pneumoniae in young children
AS Tocheva, JMC Jefferies, H Rubery, J Bennett… - Vaccine, 2011 - Elsevier
Background Asymptomatic carriage of the opportunistic pathogen Streptococcus
pneumoniae is known to precede the development of invasive disease. Young children are …
pneumoniae is known to precede the development of invasive disease. Young children are …
Global prevailing and emerging pediatric pneumococcal serotypes
EDG McIntosh, RR Reinert - Expert review of vaccines, 2011 - Taylor & Francis
Streptococcus pneumoniae is the leading cause of vaccine-preventable deaths among
children younger than 5 years of age worldwide. The 7-valent pneumococcal conjugate …
children younger than 5 years of age worldwide. The 7-valent pneumococcal conjugate …
Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era
M van der Linden, S Perniciaro, M Imöhl - BMC infectious diseases, 2015 - Springer
Background This study presents an analysis of 1,491 serogroup 23 and 762 serogroup 15
isolates from invasive pneumococcal disease (IPD) in children and adults before and after …
isolates from invasive pneumococcal disease (IPD) in children and adults before and after …
Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis
E Balsells, L Guillot, H Nair, MH Kyaw - PloS one, 2017 - journals.plos.org
Background Routine immunisation with pneumococcal conjugate vaccines (PCV7/10/13)
has reduced invasive pneumococcal disease (IPD) due to vaccine serotypes significantly …
has reduced invasive pneumococcal disease (IPD) due to vaccine serotypes significantly …
[HTML][HTML] Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands
J Spijkerman, EJM van Gils… - Emerging infectious …, 2011 - ncbi.nlm.nih.gov
To evaluate the effectiveness of the 7-valent pneumococcal conjugate vaccine (PCV7)
program, we conducted a cross-sectional observational study on nasopharyngeal carriage …
program, we conducted a cross-sectional observational study on nasopharyngeal carriage …
Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre …
C Savulescu, P Krizova, P Valentiner-Branth… - Vaccine, 2022 - Elsevier
Background Pneumococcal conjugate vaccines covering 10 (PCV10) and 13 (PCV13)
serotypes have been introduced in the infant immunization schedule of most European …
serotypes have been introduced in the infant immunization schedule of most European …
The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007
JA Bettinger, DW Scheifele, JD Kellner, SA Halperin… - Vaccine, 2010 - Elsevier
Active surveillance was conducted by the 12 centers of the Canadian Immunization
Monitoring Program, Active from 2000–2007 in children 16 years of age and younger to …
Monitoring Program, Active from 2000–2007 in children 16 years of age and younger to …
Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?
Individuals< 2 years and≥ 50 years of age, as well as those with other specific risk factors,
are especially vulnerable to invasive pneumococcal disease (IPD). Conjugate vaccines …
are especially vulnerable to invasive pneumococcal disease (IPD). Conjugate vaccines …